Leases	6 Months Ended
Leases	Jun. 30, 2020
Leases [Abstract]
Leases	Leases The Company has entered into operating leases for its new headquarters office at 9715 Key West Ave, Rockville, MD, and for its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. Contemporaneous with the USWM Acquisition, USWM Enterprises adopted ASC 842, Leases. USWM Enterprises had an existing contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of MYOBLOC (Merz Agreement). Pursuant to the Merz Agreement, Merz agreed to provide a dedicated manufacturing facility that included a stand-alone building, dedicated clean room suites, manufacturing and purification equipment, and production lines (collectively, the manufacturing facility) to manufacture MYOBLOC. The Merz Agreement will expire in July 2027, unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience. The Company concluded that the Merz Agreement contains an embedded lease, because the Company controls the use of the dedicated manufacturing facility. Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC on an annual basis, which represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility. The in-substance fixed contract consideration was allocated to the lease component, since the Company has elected not to separate lease and non-lease components. At Closing Date, the finance right of use (ROU) lease asset and corresponding lease liability relating to the dedicated manufacturing facility was $22.7 million. The finance ROU lease asset and lease liability were calculated as the present value of estimated future payments; i.e. the minimum purchase obligations as of the Closing Date, applying an incremental borrowing rate of 2.5%. The embedded lease is preliminarily classified as a finance lease. The Company recognized $0.3 million of fixed lease cost for the three and six months ended June 30, 2020. Purchases of MYOBLOC in excess of the annual minimum purchase obligations will be recorded as variable lease cost. Refer to Note 3 for further discussion of the USWM Acquisition.
Leases	Leases The Company has entered into operating leases for its new headquarters office at 9715 Key West Ave, Rockville, MD, and for its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. Contemporaneous with the USWM Acquisition, USWM Enterprises adopted ASC 842, Leases. USWM Enterprises had an existing contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of MYOBLOC (Merz Agreement). Pursuant to the Merz Agreement, Merz agreed to provide a dedicated manufacturing facility that included a stand-alone building, dedicated clean room suites, manufacturing and purification equipment, and production lines (collectively, the manufacturing facility) to manufacture MYOBLOC. The Merz Agreement will expire in July 2027, unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience. The Company concluded that the Merz Agreement contains an embedded lease, because the Company controls the use of the dedicated manufacturing facility. Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC on an annual basis, which represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility. The in-substance fixed contract consideration was allocated to the lease component, since the Company has elected not to separate lease and non-lease components. At Closing Date, the finance right of use (ROU) lease asset and corresponding lease liability relating to the dedicated manufacturing facility was $22.7 million. The finance ROU lease asset and lease liability were calculated as the present value of estimated future payments; i.e. the minimum purchase obligations as of the Closing Date, applying an incremental borrowing rate of 2.5%. The embedded lease is preliminarily classified as a finance lease. The Company recognized $0.3 million of fixed lease cost for the three and six months ended June 30, 2020. Purchases of MYOBLOC in excess of the annual minimum purchase obligations will be recorded as variable lease cost. Refer to Note 3 for further discussion of the USWM Acquisition.